Stock Track | Abbott Laboratories Plummets 10.92% Intraday After Q4 Revenue Miss and Weak Guidance

Stock Track

Jan 22

Abbott Laboratories' stock plummeted 10.92% during Thursday's intraday trading session, following the release of its fourth-quarter 2025 financial results and 2026 outlook that disappointed investors.

The healthcare products maker reported Q4 revenue of $11.46 billion, missing the consensus estimate of $11.80 billion. The revenue shortfall was driven by continued weakness in the company's diagnostics business, which saw a 2.5% decline due to lower COVID-19 testing demand, and a significant 8.9% drop in its nutrition segment.

Adding to investor concerns, Abbott issued first-quarter 2026 adjusted EPS guidance of $1.12-$1.18, which fell below the $1.20 analyst estimate. While the company's full-year adjusted EPS outlook of $5.55-$5.80 was around expectations, the combination of the revenue miss and soft near-term guidance led to the sharp selloff.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1155280235"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155280235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155280235?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155280235","market":"nz","top_or_hot":-1,"title":"Stock Track | Abbott Laboratories Plummets 10.92% Intraday After Q4 Revenue Miss and Weak Guidance","media":"Stock Track","content":"<p>Abbott Laboratories' stock plummeted 10.92% during Thursday's intraday trading session, following the release of its fourth-quarter 2025 financial results and 2026 outlook that disappointed investors.</p><p>The healthcare products maker reported Q4 revenue of $11.46 billion, missing the consensus estimate of $11.80 billion. The revenue shortfall was driven by continued weakness in the company's diagnostics business, which saw a 2.5% decline due to lower COVID-19 testing demand, and a significant 8.9% drop in its nutrition segment.</p><p>Adding to investor concerns, Abbott issued first-quarter 2026 adjusted EPS guidance of $1.12-$1.18, which fell below the $1.20 analyst estimate. While the company's full-year adjusted EPS outlook of $5.55-$5.80 was around expectations, the combination of the revenue miss and soft near-term guidance led to the sharp selloff.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Abbott Laboratories Plummets 10.92% Intraday After Q4 Revenue Miss and Weak Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Abbott Laboratories Plummets 10.92% Intraday After Q4 Revenue Miss and Weak Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-22 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Abbott Laboratories' stock plummeted 10.92% during Thursday's intraday trading session, following the release of its fourth-quarter 2025 financial results and 2026 outlook that disappointed investors.</p><p>The healthcare products maker reported Q4 revenue of $11.46 billion, missing the consensus estimate of $11.80 billion. The revenue shortfall was driven by continued weakness in the company's diagnostics business, which saw a 2.5% decline due to lower COVID-19 testing demand, and a significant 8.9% drop in its nutrition segment.</p><p>Adding to investor concerns, Abbott issued first-quarter 2026 adjusted EPS guidance of $1.12-$1.18, which fell below the $1.20 analyst estimate. While the company's full-year adjusted EPS outlook of $5.55-$5.80 was around expectations, the combination of the revenue miss and soft near-term guidance led to the sharp selloff.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"","article_id":"1155280235","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155280235","pubTimestamp":1769092597,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Abbott Laboratories' stock plummeted 10.92% during Thursday's intraday trading session, following the release of its fourth-quarter 2025 financial results and 2026 outlook that disappointed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"个股赛道|雅培制药盘中暴跌10.92%，此前Q4营收未达预期且指引疲弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1},"content_text":"Abbott Laboratories' stock plummeted 10.92% during Thursday's intraday trading session, following the release of its fourth-quarter 2025 financial results and 2026 outlook that disappointed investors.The healthcare products maker reported Q4 revenue of $11.46 billion, missing the consensus estimate of $11.80 billion. The revenue shortfall was driven by continued weakness in the company's diagnostics business, which saw a 2.5% decline due to lower COVID-19 testing demand, and a significant 8.9% drop in its nutrition segment.Adding to investor concerns, Abbott issued first-quarter 2026 adjusted EPS guidance of $1.12-$1.18, which fell below the $1.20 analyst estimate. While the company's full-year adjusted EPS outlook of $5.55-$5.80 was around expectations, the combination of the revenue miss and soft near-term guidance led to the sharp selloff.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}